Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting.

Gene therapies for rare blood disorders show promise with reduced crises and improved life quality, despite high costs and slow adoption.

CAR T-cell therapy offers hope for multiple myeloma, showing efficacy in trials but challenges in antigen targeting and tumor infiltration.

CRISPR Therapeutics faces challenges despite FDA approval for a breakthrough therapy, with slow progress impacting stock performance.

Gene therapies are very labor intensive, so despite their life-saving potential, access to and utilization of these therapies is a challenge